Impressions from the 9th Cannabinoid Conference 2017

Impressions from the 9 th Cannabinoid Conference 2017 organized by the International Association for Cannabinoid Medicines (IACM) from September 29-30, 2017 in Cologne, Germany.

by Bernd Keller, Ph.D.
Senior Research Scientist, Salvation Bioscience

The IACM Cannabinoid Conference is held every 2 years and started in 2001 ( Topics of the talks covered were mostly clinical and medical applications and patient therapies employing cannabinoids & related substances and respective legal issues in different countries around the world.

The significance of this conference is demonstrated by almost 400 attendees coming from more than 30! different countries, including 18 participants from Canada alone (


General impressions

One of the greatest frustrations observed is the many legal issues and other (e.g. financial) barriers that physicians face when trying to implement and prescribe cannabinoid medicines and therapies in their daily routine work. There is hope that novel legislation and ever improving acceptance will eventually overcome these obstacles, but this will take time and great efforts.

Another major issue reported (-that is more relevant to our business) is the often-found inaccessibility of cannabinoid medicines in sufficient quality, potency or quantity.

Physicians and clinical personnel need access to

  • Cannabinoid medicines that are produced according to current Good Manufacturing Practice (cGMP, i.e. requires FDA or similar European authorities’ approval). Different potencies and combination of active ingredients are required for different therapies.
  • Certified and consistent amounts of active ingredients (such as for example cannabinoids, and/or terpenoids). In the future, laboratories that conduct analysis will need to be certified or accredited laboratories (For example: ISO/IEC 17025 ‘General requirements for the competence of testing and calibration laboratories’, see also:
  • Reliable, consistent and long-term supply of cannabinoid/terpenoid medicines that are pesticide- (& other contaminants) free. This might require long-term relationships/contracts with growers or other suppliers. – (again testing laboratories will need to be eventually accredited – see above).